<DOC>
	<DOCNO>NCT02092077</DOCNO>
	<brief_summary>The purpose study support selection appropriate safe efficacious dose study development .</brief_summary>
	<brief_title>A Phase 2 , Safety Dose-Finding Study Treatment-Naive , Pre-Pubertal , Growth Hormone-Deficient Children</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Criteria Inclusion : Prepubertal boy ≥ 3 year ≤ 11 year prepubertal girl ≥ 3 year ≤ 10 year growth hormone ( GH ) insufficiency Diagnosis criterion consistent growth hormone research society consensus guideline Patients previously treat pituitary tumor must tumor progression least past year Physician determine rate change height less 2 standard deviation per age group . Written Informed Consent Parent legal guardian capable willing administer study drug . Other criterion apply , please contact investigator information Criteria Exclusion : Any clinically significant medical condition determine investigator , likely affect growth Contraindications rhGH treatment ; History currently active malignancy , include pituitary tumor ; Bone age , great chronological age great 9 girl great 10 boy within 3 month screen . Patients know diagnosis diabetes prediabetes Growth alter medication Allergies study medication component ; Participation another investigational study within 30 day screen Any medical condition judge investigator interfere patient participation objective study Other criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Growth Hormone-Deficient</keyword>
	<keyword>recombinant human growth hormone</keyword>
</DOC>